Canaccord Genuity analyst Mark Massaro reiterated a Hold rating on Hologic (HOLX) on January 4 and set a price target of $41. The company’s shares closed on Friday at $39.15.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 12.0% and a 53.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Currently, the analyst consensus on Hologic is a Moderate Buy with an average price target of $44.57, representing a 13.8% upside. In a report issued on January 4, Cowen & Co. also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
Based on Hologic’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $50.5 million. In comparison, last year the company had a net profit of $407 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.
